AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds 6th Patient to MS1819 Phase II Clinical Trial
Early data from the first EPI patients enrolled in clinical studies utilizing AzurRx’s MS1819 therapy shows positive results Data indicates that MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is showing a favorable safety profile and encouraging signs of efficacy and drug tolerance The study is being performed at four sites in Australia and New Zealand New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company focused on the development of recombinant protein therapies for the treatment of gastrointestinal diseases and microbiome-related conditions. Patients with exocrine pancreatic insufficiency (EPI) related to chronic pancreatitis and cystic fibrosis are…







